Smith & Nephew plc (NYSE:SNN) Shares Sold by Intellectus Partners LLC

Intellectus Partners LLC reduced its holdings in Smith & Nephew plc (NYSE:SNN) by 14.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 9,903 shares of the medical equipment provider’s stock after selling 1,689 shares during the quarter. Intellectus Partners LLC’s holdings in Smith & Nephew were worth $286,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Principal Securities Inc. raised its stake in Smith & Nephew by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 691 shares during the period. National Bank of Canada FI raised its position in shares of Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 446 shares during the period. Hara Capital LLC lifted its holdings in shares of Smith & Nephew by 391.4% in the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 1,957 shares during the last quarter. Versant Capital Management Inc boosted its position in Smith & Nephew by 1,970.2% during the 1st quarter. Versant Capital Management Inc now owns 5,217 shares of the medical equipment provider’s stock valued at $148,000 after purchasing an additional 4,965 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in Smith & Nephew by 37.4% during the 4th quarter. Quadrant Capital Group LLC now owns 7,431 shares of the medical equipment provider’s stock valued at $183,000 after purchasing an additional 2,024 shares during the period. 25.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SNN. Canaccord Genuity Group boosted their price objective on Smith & Nephew from $27.00 to $28.00 and gave the stock a “hold” rating in a research report on Thursday, May 1st. HSBC downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. UBS Group cut Smith & Nephew from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. Wall Street Zen raised Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 26th. Finally, Hsbc Global Res downgraded shares of Smith & Nephew from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.00.

Smith & Nephew Stock Performance

Shares of NYSE SNN opened at $30.28 on Friday. Smith & Nephew plc has a 1 year low of $23.69 and a 1 year high of $31.72. The firm has a market cap of $13.26 billion, a P/E ratio of 14.02, a PEG ratio of 1.26 and a beta of 0.68. The stock has a fifty day moving average price of $27.62 and a two-hundred day moving average price of $26.68. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.